AI in drug development: a capability timeline
Chart depicts the AI tools, models and milestones that unlocked new capabilities at each stage of drug development, 2019 to 2026.
How to read this
- Each dot: a tool, model or milestone, in the stage and year it appeared.
- Rows follow the pipeline; the last row spans all stages.
- Drug programs sit in the table below, not on the chart.
- Late stages look sparse because AI is newest there.
Organization (color)
DeepMind / Isomorphic
Anthropic
OpenAI
Other (biotech / academia / regulator)
AI-discovered & AI-designed drugs in the clinic
Table shows AI-discovered and AI-designed drugs now in human trials. None is approved yet (timelines and early failures, not proof it cannot happen); closest are RLY-4008 and zasocitinib.
Advancing / positive
Ongoing (early)
Discontinued / failed
| Program | Company | Indication | AI platform / tools | Ph 1 | Status (2026) | What it is |
Dates verified against primary sources (company releases, journals, clinicaltrials.gov, regulator sites).